Israel-based Valtech Cardio has received CE Mark approval for its Cardioband Mitral Reconstruction System (Cardioband), an implantable mitral reconstruction device with a transfemoral transseptal delivery system for mitral valve repair.

Cardioband is a combination of reconstruction implant, similar to surgical annuloplasty devices, with a transfemoral transseptal delivery system.

In mitral regurgitation (MR), mitral valve leaflets fail to close properly, allowing backflow of blood from the left ventricle into the left atrium during systole.

"The Cardioband was specifically designed to facilitate mitral valve repair in a first-line setting."

Approval was based on results of a multicentre feasibility trial that showed the safety and effectiveness of Cardioband in mitral valve repair and will allow the company to market and sell the system in the EU.

More than 50 patients were included in the trial, in which Cardioband was shown to significantly reduce annular size, with improvement in MR.

The product will be unveiled at the upcoming PCR London Valves meeting in Berlin, Germany.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Valtech Cardio founder Amir Gross said: "The Cardioband was specifically designed to facilitate mitral valve repair in a first-line setting while preserving the ability to perform future percutaneous or surgical valve repair and/or replacement, and the results of our multicenter clinical trial really help to demonstrate the success of this device in this indication."

If left untreated, severe MR can eventually lead to a meaningful deterioration in cardiac function and, eventually, death.

In the US, 4.2 million patients are affected by mitral valve disease, which represents a significiant market opportunity.

Cardioband allows surgical-like repair of the mitral valve annulus via a transfemoral, transseptal delivery system, allowing for real-time adjustment on a beating heart.

The company noted the transcatheter, supra-annular approach does not interfere with the mitral valve leaflets or chordae, and does not preclude subsequent treatment options if they become necessary.